Canine Oral Melanoma

Clinical Techniques in Small Animal Practice

Volumn 22, Issue 2, 2007, Pages 55-60

  Bergman, Philip J ^a  

^a ANIMAL MEDICAL CENTER   (United States)

Author keywords

chemotherapy; immunotherapy; malignant melanoma; melanoma; oral melanoma; radiation therapy; surgery; xenogeneic DNA vaccination

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; DOG; DOG DISEASE; MELANOMA; MOUTH TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANIMALS; COMBINED MODALITY THERAPY; DOG DISEASES; DOGS; MELANOMA; MOUTH NEOPLASMS; NEOPLASM STAGING;

CANIS FAMILIARIS;

EID: 34248546280     PISSN: 10962867     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ctsap.2007.03.004     Document Type: Article

References (58)

1. Smith S.H., Goldschmidt M.H., and McManus P.M. A comparative review of melanocytic neoplasms. Vet Pathol 39 6 (2002) 651-678
2. Goldschmidt M.H. Benign and malignant melanocytic neoplasms of domestic animals. Am J Dermatopathol 7 suppl (1985) 203-212
3. Todoroff R.J., and Brodey R.S. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc 175 6 (1979) 567-571
4. Wallace J., Matthiesen D.T., and Patnaik A.K. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg 21 5 (1992) 337-341
5. Hahn K.A., DeNicola D.B., Richardson R.C., et al. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 35 5 (1994) 251-256
6. Macewen E.G., Patnaik A.K., Harvey H.J., et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4 5 (1986) 397-402
7. Harvey H.J., Macewen E.G., Braun D., et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 178 6 (1981) 580-582
8. Bostock D.E. Prognosis after surgical excision of canine melanomas. Vet Pathol 16 1 (1979) 32-40
9. Spangler W.L., and Kass P.H. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Vet Pathol 43 2 (2006) 136-149
10. Modiano J.F., Ritt M.G., and Wojcieszyn J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 13 3 (1999) 163-174
11. Sulaimon S.S., and Kitchell B.E. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 17 6 (2003) 760-772
12. Goldschmidt M.H. Pigmented lesions of the skin. Clin Dermatol 12 4 (1994) 507-514
13. Vail D.M., and Macewen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18 8 (2000) 781-792
14. Bradley R.L., Macewen E.G., and Loar A.S. Mandibular resection for removal of oral tumors in 30 dogs and 6 cats. J Am Vet Med Assoc 184 4 (1984) 460-463
15. Harvey H.J. Oral tumors. Vet Clin North Am Small Anim Pract 15 3 (1985) 493-500
16. Kosovsky J.K., Matthiesen D.T., Marretta S.M., et al. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg 20 6 (1991) 397-401
17. Choi C., and Kusewitt D.F. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Vet Pathol 40 6 (2003) 713-718
18. Henry C.J., Brewer Jr. W.G., Whitley E.M., et al. Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs. J Vet Intern Med 19 5 (2005) 720-724
19. Marino D.J., Matthiesen D.T., Stefanacci J.D., et al. Evaluation of dogs with digit masses: 117 cases (1981-1991). J Am Vet Med Assoc 207 6 (1995) 726-728
20. Harmelin E.S., Holcombe R.N., Goggin J.P., et al. Acral lentiginous melanoma. J Foot Ankle Surg 37 6 (1998) 540-545
21. Freeman K.P., Hahn K.A., Harris F.D., et al. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). J Vet Intern Med 17 1 (2003) 96-101
22. Proulx D.R., Ruslander D.M., Dodge R.K., et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 44 3 (2003) 352-359
23. Theon A.P., Rodriguez C., and Madewell B.R. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 210 6 (1997) 778-784
24. Smith S.H., Goldschmidt M.H., and McManus P.M. A comparative review of melanocytic neoplasms. Vet Pathol 39 6 (2002) 651-678
25. Powers B.E. The pathology of neoplasia. In: Withrow S.J., and Macewen E.G. (Eds). Small Animal Clinical Oncology (2001), WB Saunders, Philadelphia, PA 4-17
26. Bolon B., Calderwood Mays M.B., and Hall B.J. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet Pathol 27 2 (1990) 96-102
27. Laprie C., Abadie J., Amardeilh M.F., et al. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Vet Dermatol 12 3 (2001) 139-147
28. Williams L.E., and Packer R.A. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). J Am Vet Med Assoc 222 9 (2003) 1234-1236
29. Leong S.P., Accortt N.A., Essner R., et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg 132 4 (2006) 370-373
30. Herring E.S., Smith M.M., and Robertson J.L. Lymph node staging of oral and maxillofacial neoplasms in 31 dogs and cats. J Vet Dent 19 3 (2002) 122-126
31. Nwogu C.E., Kanter P.M., and Anderson T.M. Pulmonary lymphatic mapping in dogs: use of technetium sulfur colloid and isosulfan blue for pulmonary sentinel lymph node mapping in dogs. Cancer Invest 20 7-8 (2002) 944-947
32. Yudd A.P., Kempf J.S., Goydos J.S., et al. Use of sentinel node lymphoscintigraphy in malignant melanoma. Radiographics 19 2 (1999) 343-353
33. Wells S., Bennett A., Walsh P., et al. Clinical usefulness of intradermal fluorescein and patent blue violet dyes for sentinel lymph node identification in dogs. Vet Comp Oncol 4 2 (2006) 114-122
34. Banks W.C., and Morris E. Results of radiation treatment of naturally occurring animal tumors. J Am Vet Med Assoc 166 11 (1975) 1063-1064
35. Bateman K.E., Catton P.A., Pennock P.W., et al. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 8 4 (1994) 267-272
36. Blackwood L., and Dobson J.M. Radiotherapy of oral malignant melanomas in dogs. J Am Vet Med Assoc 209 1 (1996) 98-102
37. Kitchell B.E., Brown D.M., Luck E.E., et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 204 2 (1994) 229-236
38. Theon A.P., Madewell B.R., Moore A.S., et al. Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours. Int J Hyperthermia 7 6 (1991) 881-892
39. Spugnini E.P., Dragonetti E., Vincenzi B., et al. Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma. Melanoma Res 16 1 (2006) 23-27
40. Rassnick K.M., Ruslander D.M., Cotter S.M., et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 218 9 (2001) 1444-1448
41. Boria P.A., Murry D.J., Bennett P.F., et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 224 3 (2004) 388-394
42. Page R.L., Thrall D.E., Dewhirst M.W., et al. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. Int J Hyperthermia 7 4 (1991) 559-566
43. Ogilvie G.K., Reynolds H.A., Richardson R.C., et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 195 11 (1989) 1580-1583
44. Aigner K., Hild P., Breithaupt H., et al. Isolated extremity perfusion with DTIC. An experimental and clinical study. Anticancer Res 3 2 (1983) 87-93
45. Murphy S., Hayes A.M., Blackwood L., et al. Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol 3 4 (2005) 222-229
46. O'Day S., and Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am 15 2 (2006) 419-437
47. Alexander A.N., Huelsmeyer M.K., Mitzey A., et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 55 4 (2006) 433-442
48. Hogge G.S., Burkholder J.K., Culp J., et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 6 1 (1999) 26-36
49. Macewen E.G., Kurzman I.D., Vail D.M., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 12 (1999) 4249-4258
50. Bianco S.R., Sun J., Fosmire S.P., et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 10 9 (2003) 726-736
51. Dow S.W., Elmslie R.E., Willson A.P., et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101 11 (1998) 2406-2414
52. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19 1 (2005) 56-63
53. Helfand S.C., Soergel S.A., Modiano J.F., et al. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro. Cancer Biother 9 3 (1994) 237-244
54. Guevara-Patino J.A., Turk M.J., Wolchok J.D., et al. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res 90 (2003) 157-177
55. Weber L.W., Bowne W.B., Wolchok J.D., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102 6 (1998) 1258-1264
56. Bergman P.J., Camps-Palau M.A., McKnight J.A., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24 21 (2006) 4582-4585
57. Bergman P.J., McKnight J., Novosad A., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 4 (2003) 1284-1290
58. Liao J.C., Gregor P., Wolchok J.D., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6 (2006) 8